Business
Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer\nOn track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024\nDosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN\nEntered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial\nCash position of $24.9 million provides runway through key milestones into 2025\nManagement hosting conference call and webcast today at 4:30 p.m. ET\nSAN DIEGO and CALGARY, AB, Aug. 1, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the second quarter ended June 30, 2024. All dollar amounts are expressed in Canadian currency unless otherwise noted.\n\n\"In the second quarter, we continued to build regulatory and clinical momentum for our differentiated and potentially leading immunotherapeutic agent, pelareorep, which is poised to advance to registration-enabling studies for the treatment of breast and pancreatic cancers,\" said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. \"Notably, we are pleased to have aligned with the FDA on key elements for the path forward in HR+/HER2- metastatic breast cancer (mBC). Based on guidance from regulators and compelling data from two randomized breast cancer studies, we are confident in pelareorep's potential to demonstrate a clinically meaningful benefit in a future registration-enabling study, and we remain on track to report overall survival results from the BRACELET-1 trial in the second half of 2024.\"\nMr. Pisano continued, \"In parallel, we initiated dosing in the mFOLFIRINOX cohort of the GOBLET study, an exciting opportunity to evaluate the combination of pelareorep with another first-line pancreatic cancer chemotherapy regimen that could result in a second registration program in this indication. The study builds on positive data demonstrating that the combination of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel in pancreatic cancer patients more than doubled tumor response rates compared to earli...